Omega-3 fatty acids and neurodegenerative diseases: new evidence in clinical trials
R Avallone, G Vitale, M Bertolotti - International journal of molecular …, 2019 - mdpi.com
A nutritional approach could be a promising strategy to prevent or slow the progression of
neurodegenerative diseases such as Parkinson's and Alzheimer's disease, since there is no …
neurodegenerative diseases such as Parkinson's and Alzheimer's disease, since there is no …
Omega‐3 fatty acids for the treatment of dementia
M Burckhardt, M Herke, T Wustmann… - Cochrane Database …, 2016 - cochranelibrary.com
Background Omega‐3 polyunsaturated fatty acids (omega‐3 PUFAs) from fish and plant
sources are commonly considered as a promising non‐medical alternative to improve brain …
sources are commonly considered as a promising non‐medical alternative to improve brain …
[HTML][HTML] Reversal of cognitive decline: a novel therapeutic program
DE Bredesen - Aging (Albany NY), 2014 - ncbi.nlm.nih.gov
This report describes a novel, comprehensive, and personalized therapeutic program that is
based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple …
based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple …
[HTML][HTML] Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations
P Van Dael - Nutrition research and practice, 2021 - synapse.koreamed.org
Abstract Long-chain (LC) n-3 polyunsaturated fatty acids (n-3 PUFAs), in particular
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are nutrients involved in …
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are nutrients involved in …
The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease: Acting …
Omega-3 polyunsaturated fatty acids (n‐3-PUFAs), mainly eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), may improve or prevent some psychiatric and …
docosahexaenoic acid (DHA), may improve or prevent some psychiatric and …
Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial
OBJECTIVE: To investigate the effect of a medical food on cognitive function in people with
mild Alzheimer's disease (AD). METHODS: A total of 225 drug-naïve AD patients …
mild Alzheimer's disease (AD). METHODS: A total of 225 drug-naïve AD patients …
Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance
HM Su - The Journal of nutritional biochemistry, 2010 - Elsevier
Docosahexaenoic acid (DHA, 22: 6n-3) is specifically enriched in the brain and mainly
anchored in the neuronal membrane, where it is involved in the maintenance of normal …
anchored in the neuronal membrane, where it is involved in the maintenance of normal …
n-3 fatty acids: role in neurogenesis and neuroplasticity
R Crupi, A Marino, S Cuzzocrea - Current medicinal chemistry, 2013 - ingentaconnect.com
Omega-3 polyunsaturated fatty acids (PUFA) are essential unsaturated fatty acids with a
double bond (C= C) starting after the third carbon atom from the end of the carbon chain …
double bond (C= C) starting after the third carbon atom from the end of the carbon chain …
Dietary pattern, gut microbiota, and Alzheimer's disease
Alzheimer's disease is the most common neurodegenerative disease. Until now, there has
been no specific medicine that can cure Alzheimer's disease or effectively reverse the …
been no specific medicine that can cure Alzheimer's disease or effectively reverse the …
[PDF][PDF] Citicoline: pharmacological and clinical review, 2010 update
JJ Secades - Rev Neurol, 2011 - researchgate.net
This review is based on the previous one published in 2010–Secades JJ. Citicoline:
pharmacological and clinical review, 2010 update. Rev Neurol 2011; 52 (Suppl 2): S1-62 …
pharmacological and clinical review, 2010 update. Rev Neurol 2011; 52 (Suppl 2): S1-62 …